Browsing: Sail

Conditions

J&J Secures $2.58B Option to Acquire Sail Biomedicines

By 0

Johnson & Johnson has entered a collaboration and equity investment agreement with Sail Biomedicines, a Flagship Pioneering company, to advance in vivo CAR T-cell therapies for immune-mediated diseases. As part of the agreement, Johnson & Johnson secured an exclusive option to acquire Sail for $2.58 billion. The companies will jointly advance Sail's lead in vivo…